"<h3 class="""" data-start=""87"" data-end=""107""><strong data-start=""91"" data-end=""107"">Introduction</strong></h3>
<p class="""" data-start=""109"" data-end=""579"">Blood plasma, a crucial component of human blood, plays a vital role in modern medicine. Plasma contains proteins that are essential for clotting, immune response, and various other physiological functions. The global blood plasma market has seen significant growth due to rising demand for plasma-derived therapies and increasing awareness about the importance of blood plasma in treating a wide range of diseases, including hemophilia, immune deficiencies, and burns.</p>
<p class="""" data-start=""581"" data-end=""1131"">With advancements in medical technology and an increased focus on improving patient care, the blood plasma market is expected to continue its upward trajectory. Key players in the market include global leaders such as Shanghai Raas, Octapharma, Grifols, CSL, TCS Biosciences, Sanquin, ADMA Biologics, Cerus Corp, and Baxter International. These companies play a significant role in the development and distribution of blood plasma products, making notable contributions to improving healthcare standards worldwide.</p>
<p class="""" data-start=""581"" data-end=""1131""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>
<p class="""" data-start=""1133"" data-end=""1519"">In this blog, we will delve into the profiles of major players in the blood plasma industry. We'll explore their contributions to the market, their headquarters, revenue, CAGR, and future growth prospects. Additionally, we will highlight the industry trends that are driving the expansion of the blood plasma market and discuss the implications for the future of blood plasma therapies.</p>
<h3 class="""" data-start=""1526"" data-end=""1558""><strong data-start=""1530"" data-end=""1558"">1. Shanghai Raas (China)</strong></h3>
<p class="""" data-start=""1560"" data-end=""1645""><strong data-start=""1560"" data-end=""1577"">Headquarters:</strong> Shanghai, China<br data-start=""1593"" data-end=""1596"" /> <strong data-start=""1596"" data-end=""1615"">Revenue (2023):</strong> &yen;2.3 billion<br data-start=""1628"" data-end=""1631"" /> <strong data-start=""1631"" data-end=""1640"">CAGR:</strong> 6.2%</p>
<p class="""" data-start=""1647"" data-end=""1660""><strong data-start=""1647"" data-end=""1660"">Overview:</strong></p>
<p class="""" data-start=""1662"" data-end=""2149"">Shanghai Raas is one of China&rsquo;s leading biopharmaceutical companies focused on the development, production, and commercialization of blood plasma-derived products. Established in 2001, the company has grown to become a significant player in the global blood plasma market. Shanghai Raas specializes in the production of human albumin, immunoglobulin (IVIG), and coagulation factor concentrates, essential for treating a variety of diseases such as hemophilia and immune system disorders.</p>
<p class="""" data-start=""2151"" data-end=""2484"">The company has made considerable strides in advancing the technology and quality of plasma-derived products. By focusing on expanding its product offerings and increasing its manufacturing capacity, Shanghai Raas has solidified its position in the Asia-Pacific region and is making significant inroads into the international market.</p>
<p class="""" data-start=""2486"" data-end=""2785"">Shanghai Raas&rsquo;s strong focus on research and development (R&amp;D) has allowed the company to improve the safety, efficacy, and quality of its blood plasma products. The company is also working on expanding its presence in emerging markets, where there is increasing demand for plasma-derived therapies.</p>
<p class="""" data-start=""2787"" data-end=""2804""><strong data-start=""2787"" data-end=""2804"">Key Products:</strong></p>
<ul data-start=""2806"" data-end=""2907"">
<li class="""" data-start=""2806"" data-end=""2821"">
<p class="""" data-start=""2808"" data-end=""2821"">Human albumin</p>
</li>
<li class="""" data-start=""2822"" data-end=""2845"">
<p class="""" data-start=""2824"" data-end=""2845"">Immunoglobulin (IVIG)</p>
</li>
<li class="""" data-start=""2846"" data-end=""2879"">
<p class="""" data-start=""2848"" data-end=""2879"">Coagulation factor concentrates</p>
</li>
<li class="""" data-start=""2880"" data-end=""2907"">
<p class="""" data-start=""2882"" data-end=""2907"">Plasma collection systems</p>
</li>
</ul>
<p><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>
<p class="""" data-start=""2909"" data-end=""2950""><strong data-start=""2909"" data-end=""2950"">Market Position and Future Prospects:</strong></p>
<p class="""" data-start=""2952"" data-end=""3240"">Shanghai Raas is poised to benefit from the growing demand for blood plasma products, particularly in the Asia-Pacific region. The company&rsquo;s commitment to increasing its production capacity and expanding its R&amp;D efforts will likely contribute to its sustained growth in the global market.</p>
<h3 class="""" data-start=""3247"" data-end=""3282""><strong data-start=""3251"" data-end=""3282"">2. Octapharma (Switzerland)</strong></h3>
<p class="""" data-start=""3284"" data-end=""3376""><strong data-start=""3284"" data-end=""3301"">Headquarters:</strong> Lachen, Switzerland<br data-start=""3321"" data-end=""3324"" /> <strong data-start=""3324"" data-end=""3343"">Revenue (2023):</strong> CHF 2.2 billion<br data-start=""3359"" data-end=""3362"" /> <strong data-start=""3362"" data-end=""3371"">CAGR:</strong> 5.5%</p>
<p class="""" data-start=""3378"" data-end=""3391""><strong data-start=""3378"" data-end=""3391"">Overview:</strong></p>
<p class="""" data-start=""3393"" data-end=""3825"">Octapharma, a global leader in the development and production of human proteins, is another major player in the blood plasma market. Headquartered in Switzerland, Octapharma focuses on producing plasma-derived medicines used in the treatment of hemophilia, immune deficiencies, and other life-threatening conditions. The company has a broad product portfolio that includes immunoglobulins, clotting factor concentrates, and albumin.</p>
<p class="""" data-start=""3827"" data-end=""4109"">Octapharma has established a strong presence in Europe, North America, and other international markets. It operates several manufacturing facilities, primarily dedicated to plasma fractionation, and also collaborates with blood centers worldwide to ensure a steady supply of plasma.</p>
<p class="""" data-start=""4111"" data-end=""4363"">The company&rsquo;s focus on quality, patient care, and innovation has enabled Octapharma to maintain its competitive edge in the blood plasma market. The company continues to invest in R&amp;D, aiming to enhance the efficacy and safety profiles of its products.</p>
<p class="""" data-start=""4365"" data-end=""4382""><strong data-start=""4365"" data-end=""4382"">Key Products:</strong></p>
<ul data-start=""4384"" data-end=""4481"">
<li class="""" data-start=""4384"" data-end=""4399"">
<p class="""" data-start=""4386"" data-end=""4399"">Human albumin</p>
</li>
<li class="""" data-start=""4400"" data-end=""4423"">
<p class="""" data-start=""4402"" data-end=""4423"">Immunoglobulin (IVIG)</p>
</li>
<li class="""" data-start=""4424"" data-end=""4457"">
<p class="""" data-start=""4426"" data-end=""4457"">Coagulation factor concentrates</p>
</li>
<li class="""" data-start=""4458"" data-end=""4481"">
<p class="""" data-start=""4460"" data-end=""4481"">Hyperimmune globulins</p>
</li>
</ul>
<p><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>
<p class="""" data-start=""4483"" data-end=""4524""><strong data-start=""4483"" data-end=""4524"">Market Position and Future Prospects:</strong></p>
<p class="""" data-start=""4526"" data-end=""4849"">With its strong product offerings and expanding global reach, Octapharma is well-positioned to capitalize on the growing demand for plasma-derived therapies. The company&rsquo;s commitment to continuous improvement in the quality of its products and increasing market penetration bodes well for its future growth in the industry.</p>
<h3 class="""" data-start=""4856"" data-end=""4882""><strong data-start=""4860"" data-end=""4882"">3. Grifols (Spain)</strong></h3>
<p class="""" data-start=""4884"" data-end=""4970""><strong data-start=""4884"" data-end=""4901"">Headquarters:</strong> Barcelona, Spain<br data-start=""4918"" data-end=""4921"" /> <strong data-start=""4921"" data-end=""4940"">Revenue (2023):</strong> &euro;6.2 billion<br data-start=""4953"" data-end=""4956"" /> <strong data-start=""4956"" data-end=""4965"">CAGR:</strong> 7.1%</p>
<p class="""" data-start=""4972"" data-end=""4985""><strong data-start=""4972"" data-end=""4985"">Overview:</strong></p>
<p class="""" data-start=""4987"" data-end=""5462"">Grifols is a multinational pharmaceutical company that specializes in the collection, manufacture, and distribution of blood plasma products. Headquartered in Barcelona, Spain, Grifols is a global leader in plasma-derived therapies, offering products for the treatment of hemophilia, immunodeficiencies, and other serious medical conditions. Grifols operates a comprehensive network of blood collection centers, manufacturing plants, and research facilities around the world.</p>
<p class="""" data-start=""5464"" data-end=""5721"">Grifols has an extensive range of plasma-derived products, including immunoglobulins (IVIG), albumin, and clotting factors. The company has also made significant advancements in the development of technologies used for plasma fractionation and purification.</p>
<p class="""" data-start=""5723"" data-end=""5740""><strong data-start=""5723"" data-end=""5740"">Key Products:</strong></p>
<ul data-start=""5742"" data-end=""5855"">
<li class="""" data-start=""5742"" data-end=""5765"">
<p class="""" data-start=""5744"" data-end=""5765"">Immunoglobulin (IVIG)</p>
</li>
<li class="""" data-start=""5766"" data-end=""5781"">
<p class="""" data-start=""5768"" data-end=""5781"">Human albumin</p>
</li>
<li class="""" data-start=""5782"" data-end=""5815"">
<p class="""" data-start=""5784"" data-end=""5815"">Coagulation factor concentrates</p>
</li>
<li class="""" data-start=""5816"" data-end=""5855"">
<p class="""" data-start=""5818"" data-end=""5855"">Diagnostics and blood typing products</p>
</li>
</ul>
<p class="""" data-start=""5857"" data-end=""5898""><strong data-start=""5857"" data-end=""5898"">Market Position and Future Prospects:</strong></p>
<p class="""" data-start=""5900"" data-end=""6245"">Grifols&rsquo; dominant position in the global plasma market is reinforced by its strong distribution network, manufacturing capabilities, and leadership in R&amp;D. The company&rsquo;s revenue and market share continue to grow, and it is poised for continued expansion, particularly in emerging markets, where the demand for plasma-derived therapies is rising.</p>
<p class="""" data-start=""5900"" data-end=""6245""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>
<h3 class="""" data-start=""6252"" data-end=""6278""><strong data-start=""6256"" data-end=""6278"">4. CSL (Australia)</strong></h3>
<p class="""" data-start=""6280"" data-end=""6379""><strong data-start=""6280"" data-end=""6297"">Headquarters:</strong> Parkville, Victoria, Australia<br data-start=""6328"" data-end=""6331"" /> <strong data-start=""6331"" data-end=""6350"">Revenue (2023):</strong> $11.8 billion<br data-start=""6364"" data-end=""6367"" /> <strong data-start=""6367"" data-end=""6376"">CAGR:</strong> 9%</p>
<p class="""" data-start=""6381"" data-end=""6394""><strong data-start=""6381"" data-end=""6394"">Overview:</strong></p>
<p class="""" data-start=""6396"" data-end=""6753"">CSL, a global biotechnology company, has been a major player in the blood plasma market for many years. The company is renowned for its extensive portfolio of plasma-derived therapies used to treat conditions such as hemophilia, immunodeficiencies, and other rare diseases. CSL&rsquo;s offerings include immunoglobulins, clotting factor concentrates, and albumin.</p>
<p class="""" data-start=""6755"" data-end=""7083"">CSL operates an extensive network of blood collection centers and manufacturing facilities globally, ensuring a consistent and reliable supply of plasma for its products. The company is also a leader in the development of new therapies, investing heavily in R&amp;D to improve the efficacy and safety of its plasma-derived products.</p>
<p class="""" data-start=""7085"" data-end=""7102""><strong data-start=""7085"" data-end=""7102"">Key Products:</strong></p>
<ul data-start=""7104"" data-end=""7217"">
<li class="""" data-start=""7104"" data-end=""7127"">
<p class="""" data-start=""7106"" data-end=""7127"">Immunoglobulin (IVIG)</p>
</li>
<li class="""" data-start=""7128"" data-end=""7143"">
<p class="""" data-start=""7130"" data-end=""7143"">Human albumin</p>
</li>
<li class="""" data-start=""7144"" data-end=""7177"">
<p class="""" data-start=""7146"" data-end=""7177"">Coagulation factor concentrates</p>
</li>
<li class="""" data-start=""7178"" data-end=""7217"">
<p class="""" data-start=""7180"" data-end=""7217"">Specialty therapies for rare diseases</p>
</li>
</ul>
<p class="""" data-start=""7219"" data-end=""7260""><strong data-start=""7219"" data-end=""7260"">Market Position and Future Prospects:</strong></p>
<p class="""" data-start=""7262"" data-end=""7543"">CSL&rsquo;s leadership in the plasma market, combined with its strong focus on innovation and growth, ensures the company will continue to thrive. With increasing demand for plasma-based therapies and a growing global presence, CSL is positioned for sustained growth in the coming years.</p>
<h3 class="""" data-start=""7550"" data-end=""7581""><strong data-start=""7554"" data-end=""7581"">5. TCS Biosciences (UK)</strong></h3>
<p class="""" data-start=""7583"" data-end=""7676""><strong data-start=""7583"" data-end=""7600"">Headquarters:</strong> Abingdon, Oxfordshire, UK<br data-start=""7626"" data-end=""7629"" /> <strong data-start=""7629"" data-end=""7648"">Revenue (2023):</strong> &pound;500 million<br data-start=""7661"" data-end=""7664"" /> <strong data-start=""7664"" data-end=""7673"">CAGR:</strong> 4%</p>
<p class="""" data-start=""7583"" data-end=""7676""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>
<p class="""" data-start=""7678"" data-end=""7691""><strong data-start=""7678"" data-end=""7691"">Overview:</strong></p>
<p class="""" data-start=""7693"" data-end=""8028"">TCS Biosciences is a UK-based company that specializes in providing innovative solutions for plasma collection, fractionation, and processing. Although a smaller player compared to some of the larger multinational companies, TCS Biosciences has built a reputation for its high-quality products and services in the blood plasma sector.</p>
<p class="""" data-start=""8030"" data-end=""8333"">The company&rsquo;s range of offerings includes plasma fractionation systems, blood collection products, and diagnostic kits for plasma screening. TCS Biosciences also provides tailored solutions for blood banks and plasma centers worldwide, ensuring compliance with global regulations and industry standards.</p>
<p class="""" data-start=""8335"" data-end=""8352""><strong data-start=""8335"" data-end=""8352"">Key Products:</strong></p>
<ul data-start=""8354"" data-end=""8512"">
<li class="""" data-start=""8354"" data-end=""8386"">
<p class="""" data-start=""8356"" data-end=""8386"">Plasma fractionation equipment</p>
</li>
<li class="""" data-start=""8387"" data-end=""8414"">
<p class="""" data-start=""8389"" data-end=""8414"">Plasma collection systems</p>
</li>
<li class="""" data-start=""8415"" data-end=""8452"">
<p class="""" data-start=""8417"" data-end=""8452"">Blood typing and screening products</p>
</li>
<li class="""" data-start=""8453"" data-end=""8512"">
<p class="""" data-start=""8455"" data-end=""8512"">Research and diagnostic kits for plasma-derived therapies</p>
</li>
</ul>
<p class="""" data-start=""8514"" data-end=""8555""><strong data-start=""8514"" data-end=""8555"">Market Position and Future Prospects:</strong></p>
<p class="""" data-start=""8557"" data-end=""8841"">TCS Biosciences is well-positioned to benefit from the growing need for advanced plasma collection and processing systems. As the demand for plasma-derived products increases, TCS Biosciences' specialized solutions are likely to see growing demand, particularly in developing regions.</p>
<h3 class="""" data-start=""8848"" data-end=""8880""><strong data-start=""8852"" data-end=""8880"">6. Sanquin (Netherlands)</strong></h3>
<p class="""" data-start=""8882"" data-end=""8974""><strong data-start=""8882"" data-end=""8899"">Headquarters:</strong> Amsterdam, Netherlands<br data-start=""8922"" data-end=""8925"" /> <strong data-start=""8925"" data-end=""8944"">Revenue (2023):</strong> &euro;800 million<br data-start=""8957"" data-end=""8960"" /> <strong data-start=""8960"" data-end=""8969"">CAGR:</strong> 3.5%</p>
<p class="""" data-start=""8976"" data-end=""8989""><strong data-start=""8976"" data-end=""8989"">Overview:</strong></p>
<p class="""" data-start=""8991"" data-end=""9425"">Sanquin is a major Dutch blood bank and supplier of blood plasma products. The company operates blood collection centers across the Netherlands and specializes in plasma fractionation for the production of immunoglobulins, albumin, and clotting factor concentrates. Sanquin&rsquo;s focus on plasma donation and its commitment to ensuring a sustainable supply of blood plasma have helped it maintain a strong position in the European market.</p>
<p class="""" data-start=""8991"" data-end=""9425""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>
<p class="""" data-start=""9427"" data-end=""9673"">Sanquin also engages in research and development to improve the efficacy and safety of plasma-derived therapies. The company collaborates with other healthcare organizations to advance the development of new treatments for blood-related diseases.</p>
<p class="""" data-start=""9675"" data-end=""9692""><strong data-start=""9675"" data-end=""9692"">Key Products:</strong></p>
<ul data-start=""9694"" data-end=""9808"">
<li class="""" data-start=""9694"" data-end=""9718"">
<p class="""" data-start=""9696"" data-end=""9718"">Immunoglobulins (IVIG)</p>
</li>
<li class="""" data-start=""9719"" data-end=""9728"">
<p class="""" data-start=""9721"" data-end=""9728"">Albumin</p>
</li>
<li class="""" data-start=""9729"" data-end=""9762"">
<p class="""" data-start=""9731"" data-end=""9762"">Coagulation factor concentrates</p>
</li>
<li class="""" data-start=""9763"" data-end=""9808"">
<p class="""" data-start=""9765"" data-end=""9808"">Plasma-derived treatments for rare diseases</p>
</li>
</ul>
<p class="""" data-start=""9810"" data-end=""9851""><strong data-start=""9810"" data-end=""9851"">Market Position and Future Prospects:</strong></p>
<p class="""" data-start=""9853"" data-end=""10172"">Sanquin&rsquo;s strong reputation in the European market, along with its focus on sustainable plasma sourcing and innovative research, positions it well for continued growth. As demand for blood plasma products increases globally, Sanquin&rsquo;s extensive experience in plasma collection and fractionation will remain a key asset.</p>
<h3 class="""" data-start=""10179"" data-end=""10210""><strong data-start=""10183"" data-end=""10210"">7. ADMA Biologics (USA)</strong></h3>
<p class="""" data-start=""10212"" data-end=""10303""><strong data-start=""10212"" data-end=""10229"">Headquarters:</strong> Ramsey, New Jersey, USA<br data-start=""10253"" data-end=""10256"" /> <strong data-start=""10256"" data-end=""10275"">Revenue (2023):</strong> $160 million<br data-start=""10288"" data-end=""10291"" /> <strong data-start=""10291"" data-end=""10300"">CAGR:</strong> 8%</p>
<p class="""" data-start=""10305"" data-end=""10318""><strong data-start=""10305"" data-end=""10318"">Overview:</strong></p>
<p class="""" data-start=""10320"" data-end=""10658"">ADMA Biologics is a U.S.-based biopharmaceutical company that develops, manufactures, and commercializes blood plasma-derived products for the treatment of immune deficiencies and other serious diseases. The company&rsquo;s product portfolio includes immunoglobulins, clotting factors, and other specialized therapies derived from human plasma.</p>
<p class="""" data-start=""10660"" data-end=""10941"">ADMA Biologics focuses on creating safe and effective therapies for patients with rare and chronic diseases. With a state-of-the-art manufacturing facility in the U.S., the company is committed to providing high-quality blood plasma-derived products and improving patient outcomes.</p>
<p class="""" data-start=""10660"" data-end=""10941""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>
<p class="""" data-start=""10943"" data-end=""10960""><strong data-start=""10943"" data-end=""10960"">Key Products:</strong></p>
<ul data-start=""10962"" data-end=""11062"">
<li class="""" data-start=""10962"" data-end=""10986"">
<p class="""" data-start=""10964"" data-end=""10986"">Immunoglobulins (IVIG)</p>
</li>
<li class="""" data-start=""10987"" data-end=""11017"">
<p class="""" data-start=""10989"" data-end=""11017"">Clotting factor concentrates</p>
</li>
<li class="""" data-start=""11018"" data-end=""11062"">
<p class="""" data-start=""11020"" data-end=""11062"">Plasma-derived therapies for rare diseases</p>
</li>
</ul>
<p class="""" data-start=""11064"" data-end=""11105""><strong data-start=""11064"" data-end=""11105"">Market Position and Future Prospects:</strong></p>
<p class="""" data-start=""11107"" data-end=""11359"">ADMA Biologics is growing rapidly due to the increasing demand for blood plasma therapies. The company&rsquo;s strategic focus on expanding its product portfolio and increasing its manufacturing capacity will continue to drive its growth in the coming years.</p>
<h3 class="""" data-start=""11366"" data-end=""11384""><strong data-start=""11370"" data-end=""11384"">Conclusion</strong></h3>
<p class="""" data-start=""11386"" data-end=""12027"">The blood plasma market is undergoing significant growth, driven by increasing demand for plasma-derived therapies to treat a wide range of medical conditions. Companies such as <strong data-start=""11564"" data-end=""11581"">Shanghai Raas</strong>, <strong data-start=""11583"" data-end=""11597"">Octapharma</strong>, <strong data-start=""11599"" data-end=""11610"">Grifols</strong>, <strong data-start=""11612"" data-end=""11619"">CSL</strong>, <strong data-start=""11621"" data-end=""11640"">TCS Biosciences</strong>, <strong data-start=""11642"" data-end=""11653"">Sanquin</strong>, <strong data-start=""11655"" data-end=""11673"">ADMA Biologics</strong>, <strong data-start=""11675"" data-end=""11689"">Cerus Corp</strong>, and <strong data-start=""11695"" data-end=""11719"">Baxter International</strong> are playing pivotal roles in advancing the industry and meeting the rising demand for high-quality plasma-derived products. These companies' investments in research and development, product innovation, and global market expansion are likely to fuel the growth of the blood plasma market in the coming years.</p>
<p class="""" data-start=""12029"" data-end=""12385"">As the healthcare industry continues to prioritize the use of plasma-derived therapies for treating chronic diseases and rare conditions, the market for blood plasma products will continue to evolve. With continued advancements in manufacturing technologies and a commitment to improving patient care, the future of the blood plasma market looks promising.</p>
<p class="""" data-start=""12029"" data-end=""12385""><strong>To Learn more about this Report, Request Free Sample PDF @&nbsp;<a href=""https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603"">https://www.globalmarketstatistics.com/market-reports/blood-plasma-market-12603</a></strong></p>"
